research news

Thendor Therapeutics today announced the issuance of U.S. Patent No. 12,721,881 by the United States Patent and Trademark Office, covering the treatment of fibrotic diseases using Thendor's proprietary peptides. The patented treatment methods were invented by Carol Feghali-Bostwick, PhD, scientific founder of Thendor and Distinguished University Professor at the Medical University of South Carolina (MUSC) and are included in technology exclusively licensed from the Zucker Institute for Innovation Commercialization, the commercialization entity for MUSC. The new patent protects the treatment of systemic and organ-specific fibrotic diseases using peptides that Thendor has been evaluating.

Dr. Carol Feghali-Bostwick (Medical University of South Carolina) presented at the 2026 World Congress of Basic & Clinical Pharmacology (WCP 2026) with her presentation, "Targeting Collagen with Collagen for the Treatment of Organ Fibrosis." Her presentation highlighted collagen-targeted approaches for organ fibrosis and advances in extracellular matrix (ECM) biology. The symposium brought together leading international researchers to discuss emerging anti-fibrotic therapies, extracellular matrix remodeling, and novel therapeutic strategies across multiple fibrotic diseases.

Thendor Therapeutics is presenting at the 2026 MTEC Annual Meeting, showcasing our peptide-based anti-fibrotic platform and its potential applications across multiple fibrotic conditions, including exposure-induced fibrosis relevant to medical countermeasure development.  CEO Steven King will be available at Poster #37 to discuss the platform and answer questions.   The MTEC Annual Meeting brings together government, industry, and academic stakeholders advancing medical solutions for warfighter health and national preparedness.

A novel anti-fibrotic endostatin peptide derived from collagen (TTX-001) demonstrated significant reductions in markers of inflammation and fibrosis in human penile and urethral tissues ex vivo. Findings suggest TTX-001 may represent a promising non-surgical therapeutic intervention for chronic fibrotic urological conditions.

MUSC researchers show that patients with scleroderma and lung fibrosis have too little of the antifibrotic protein Cathepsin L. This finding opens new pathways for therapeutic intervention by focusing on increasing antifibrotic proteins rather than just reducing profibrotic ones.

Research team identifies the mechanism by which the E4 peptide reverses fibrosis in multiple organs. The peptide activates the urokinase pathway, providing a possible clinical solution for patients with fibrosis across different organ systems.

Lysyl oxidase (LOX) plays multiple important roles in promoting fibrosis and shows promise as a biomarker for monitoring treatment response. This "moonlighting" molecule offers new insights into disease progression and therapeutic monitoring.